Barbara Troupin

Dr. Troupin has more than 20 years of pharmaceutical industry leadership experience across Medical Affairs, Clinical Development, and Regulatory Affairs in small, private and publicly traded pharmaceutical companies in the U.S. and Europe. In her current role as Senior Vice President Medical Affairs, Dr. Troupin is focused on building out the Medical Affairs functions to drive towards and support a successful launch for mavacamten as well as initiating further landscape development across the portfolio.

Previously, she served as Chief Medical Officer at ERX Pharmaceuticals, a small, virtual drug development start-up in the metabolic space. Prior to that she served as CMO and VP Clinical Development & Regulatory Affairs at Aquinox Pharmaceuticals and SVP Clinical Development and CMO at Apricus Biosciences. Prior to that, while at VIVUS, she held roles in Clinical Development and subsequently Medical Affairs, leading clinical and medical teams in the development, approval, and launch of Qsymia for the treatment of obesity. Dr. Troupin has been a key member of the leadership team for 3 NDAs, 2 MAAs, and a U.S.-focus launch, as well as assuring alignment of partner and European launches. She has strategic leadership experience in building and growing teams, departments and companies, pipeline optimization, regulatory affairs and label negotiation, partnering and fundraising, and key stakeholder relationship nurturing. Dr. Troupin completed her medical degree at the University of Pennsylvania, her M.B.A. at The Wharton School of Business both in Philadelphia, and Family Medicine Residency in San Diego.